Immutep IMMP
NASDAQ IMMP
$0.39 0.00 (-1.28%)
At close: Aug 21, 2026 · 4:00 PM EDT

Immutep (IMMP) Net Income towards Common Stockholders (2011 - 2025)

Immutep's (IMMP) quarterly Net Income towards Common Stockholders came in at $64.9 million in Q4 2025, down 42.43% YoY from $112.8 million in Q4 2024, and down 29.41% on a QoQ basis from $92.0 million in Q2 2025.

Immutep (IMMP) Net Income towards Common Stockholders (2011 - 2025) Analysis & Trends

Immutep (IMMP) has 13 years of Net Income towards Common Stockholders data on file, last reported at $64.9 million in Q4 2025.

  • Quarterly Net Income towards Common Stockholders fell 42.43% year-over-year to $64.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $394.6 million (down 2.37% YoY) and the FY2025 annual result came in at $92.0 million, down 26.35% from the prior year.
  • Net Income towards Common Stockholders declined to $64.9 million in Q4 2025, from $92.0 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $124.9 million in Q2 2024 to a low of $50.4 million in Q4 2022.
  • A 5-year average of $81.5 million and a median of $77.3 million in 2021 frame the typical range for Net Income towards Common Stockholders.
  • Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders jumped 158.52% — and 2025, when it tumbled 42.43%.
  • Tracing IMMP's Net Income towards Common Stockholders over 5 years: stood at $79.3 million in 2021, then tumbled by 36.48% to $50.4 million in 2022, then jumped by 49.41% to $75.3 million in 2023, then surged by 49.82% to $112.8 million in 2024, then plunged by 42.43% to $64.9 million in 2025.
  • The last three Net Income towards Common Stockholders figures came in at $64.9 million (Q4 2025), $92.0 million (Q2 2025), and $112.8 million (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 472.00 Mn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -782.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 237.01 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 164.49 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -174.37 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -13.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 81.49 Mn
10 Immutep 56.46 Mn -8.63 Mn - 64.93 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 64.93 Mn
Jun 30, 2025 91.99 Mn
Dec 31, 2024 112.79 Mn
Jun 30, 2024 124.90 Mn
Dec 31, 2023 75.28 Mn
Jun 30, 2023 91.21 Mn
Dec 31, 2022 50.39 Mn
Jun 30, 2022 67.38 Mn
Dec 31, 2021 79.32 Mn
Jun 30, 2021 56.42 Mn
Dec 31, 2020 44.36 Mn
Jun 30, 2020 21.83 Mn
Dec 31, 2019 19.15 Mn
Jun 30, 2019 17.08 Mn
Dec 31, 2018 24.05 Mn
Jun 30, 2018 25.38 Mn
Jun 30, 2017 -2.31 Mn
Mar 31, 2017 -1.69 Mn
Dec 31, 2016 -47,793.34
Jun 30, 2016 -2.63 Mn